Recent federal court rulings have significantly limited access to the widely used abortion pill mifepristone, particularly by mail and through telehealth services. In a series of decisions, appeals courts have blocked plans that would allow the distribution of mifepristone via mail, raising concerns among advocates and lawmakers. The Supreme Court is now being asked to intervene and restore mail-order access to the medication. Reactions have been swift, with Democrats and reproductive rights advocates expressing outrage over what they see as an infringement on abortion rights, urging for continued resistance against the restrictions. As the legal battle unfolds, many providers are adapting to the new landscape of abortion access amidst the ongoing conflict over telehealth prescriptions.